Organogenesis (NASDAQ:ORGO) Stock Rating Upgraded by Wall Street Zen

Organogenesis (NASDAQ:ORGO) was upgraded by investment analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a note issued to investors on Sunday.

Several other analysts also recently weighed in on ORGO. BTIG Research lowered their price target on shares of Organogenesis from $9.00 to $8.00 and set a “buy” rating for the company in a research note on Friday, February 27th. Weiss Ratings raised Organogenesis from a “sell (d+)” rating to a “hold (c)” rating in a research note on Friday, February 27th. Two analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $8.50.

Organogenesis Stock Down 1.1%

Shares of NASDAQ ORGO opened at $2.76 on Friday. The stock has a market capitalization of $355.05 million, a P/E ratio of 34.50 and a beta of 1.43. Organogenesis has a one year low of $2.61 and a one year high of $7.08. The firm’s 50 day simple moving average is $3.89 and its two-hundred day simple moving average is $4.51. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.62 and a quick ratio of 3.32.

Organogenesis (NASDAQ:ORGO) last announced its quarterly earnings data on Thursday, February 26th. The company reported $0.31 earnings per share for the quarter, topping analysts’ consensus estimates of $0.21 by $0.10. Organogenesis had a net margin of 5.32% and a return on equity of 21.41%. The firm had revenue of $225.61 million during the quarter, compared to analyst estimates of $172.68 million. As a group, analysts expect that Organogenesis will post -0.07 EPS for the current fiscal year.

Insider Transactions at Organogenesis

In other Organogenesis news, Director Glenn H. Nussdorf sold 200,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $5.14, for a total transaction of $1,028,000.00. Following the completion of the transaction, the director owned 2,565,591 shares of the company’s stock, valued at $13,187,137.74. This represents a 7.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 33.00% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Organogenesis

A number of large investors have recently made changes to their positions in the business. State of Alaska Department of Revenue purchased a new position in shares of Organogenesis during the third quarter valued at approximately $25,000. Quarry LP purchased a new stake in Organogenesis in the third quarter worth $25,000. Flagship Harbor Advisors LLC bought a new stake in Organogenesis in the fourth quarter valued at $34,000. Federated Hermes Inc. boosted its holdings in Organogenesis by 52.8% in the fourth quarter. Federated Hermes Inc. now owns 8,541 shares of the company’s stock valued at $44,000 after acquiring an additional 2,953 shares in the last quarter. Finally, Walleye Capital LLC purchased a new position in Organogenesis during the 2nd quarter valued at $45,000. 49.57% of the stock is currently owned by institutional investors.

About Organogenesis

Organogenesis Inc operates as a regenerative medicine company focused on the development, manufacturing and commercialization of therapeutic solutions for wound care, surgical repair and sports medicine. The company’s product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. Organogenesis markets its therapies to hospitals, outpatient clinics, wound care centers and other healthcare providers.

Key offerings include Apligraf, a living skin substitute for treatment of diabetic foot ulcers and venous leg ulcers; Dermagraft, a cryopreserved human fibroblast-derived dermal substitute; Grafix, a placental membrane allograft for complex and chronic wounds; and TheraSkin, a cryopreserved human skin allograft used in surgical and reconstructive procedures.